Table 1.

Clinical characteristics of patients at baseline and during follow-up

All Patients (n = 235)
Characteristics at baseline
    age (years)61.7 ± 14.0
    gender (male/female), n (%)146 (62.1)/89 (37.9)
    body mass indexa26.1 ± 4.5
Start of dialysis with
    hemodialysis197 (83.8)
    peritoneal dialysis38 (16.2)
Diabetes mellitus82 (34.9)
Systolic BP (mmHg)154.0 ± 22.7
Diastolic BP (mmHg)83.0 ± 12.3
Mean ± SD25th; 50th; 75th Percentile
Laboratory parameters at baseline
    albumin (g/dl)3.71 ± 0.653.30; 3.70; 4.20
    phosphorus (mmol/L)1.98 ± 0.611.57; 1.94; 2.30
    calcium (mmol/L)2.12 ± 0.271.98; 2.14; 2.30
    iPTH (pg/ml)350.5 ± 264.9156.5; 287.2; 468.7
    hemoglobin (g/dl)11.17 ± 1.7210.10; 11.30; 12.30
    creatinine (mg/dl)7.28 ± 2.645.50; 6.80; 8.60
    C-reactive protein (mg/dl)3.24 ± 5.340.30; 0.98; 3.00
    bicarbonate (mmol/L)21.0 ± 3.618.7; 21.0; 23.4
    ferritin (ng/ml)174.3 ± 206.544.0; 111.0; 234.0
    total cholesterol (mg/dl)189.8 ± 51.0152.0; 184.0; 219.5
    leukocytes (g/L)8.18 ± 3.296.10; 7.40; 9.90
    Kt/V1.29 ± 0.411.10; 1.20; 1.43
Comorbidities at baseline
    CADb40 (17.0)
    CVDc70 (29.8)
    PADd40 (17.0)
Follow-up
    follow-up time (months)e38.9 ± 23.2
    transplantation58 (24.7)
    all-cause mortality82 (34.9)
Medications during follow-up
    phosphate binder217 (92.3)
    calcium-based209 (88.9)
    aluminum-based22 (9.4)
    sevelamer-HCl125 (53.2)
    erythropoietin234 (99.6)
    iron supplements204 (86.8)
    calcitriol155 (66)
  • Values are mean ± SD or number with percentage in parentheses. iPTH, immunoreactive parathyroid hormone.

  • a Calculated as weight in kilograms divided by height in meters squared (kg/m2).

  • b Coronary artery disease (CAD): myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), aortocoronary bypass (ACBP).

  • c Cardiovascular disease (CVD): myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), aortocoronary bypass (ACBP), coronary artery stenosis ≥50%, ischemic cerebral infarction, transient ischemic attack (TIA)/prolonged reversible ischemic neurological deficit (PRIND).

  • d PAD (peripheral arterial disease): arterial stenosis, percutaneous transluminal angioplasty (PTA), peripheral bypass, amputation.

  • e Follow-up time was calculated as the time from the start of dialysis until the patient died or the end of the observation period (December 31, 2007) was reached.